CLINICAL TRIAL: KAMADA-API
临床试验:Kamada-API
基本信息
- 批准号:7717137
- 负责人:
- 金额:$ 12.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-12-01 至 2008-11-30
- 项目状态:已结题
- 来源:
- 关键词:ApisBiochemicalBloodClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseEnrollmentFundingGrantInformed ConsentInfusion proceduresInstitutionMedical HistoryPhysical ExaminationProlastinRandomizedResearchResearch PersonnelResourcesScreening procedureSourceUnited States National Institutes of HealthWeekfollow-upmicrobial alkaline proteinase inhibitortreatment centertreatment durationvirology
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Approximately 50 subjects will be enrolled in at least 3 treatment centers in the US. This study is expected to take about 12 months and the subjects will be actively involved for 28 weeks out of which 24 weeks are treatment period and a follow up period which occurs 4 weeks after the final treatment. The trial will include two subsets. In the first one, all subjects will be randomly assigned to receive weekly infusions of either the Kamada-API or Prolastin in a 2 to 1 fashion. That is for every two subjects randomly selected to receive Kamada-API one will be randomly selected to receive Prolastin. Following signing of an informed consent, screening procedures will be done, including vitals signs, medical history, physical examination, hematological and biochemical analyses, and virology blood draws. If applicable, subjects currently on API therapy will undergo a 5-week washout period during which they will receive no API. At least 6 subjects will be included.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK Louis BRANTLY其他文献
MARK Louis BRANTLY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK Louis BRANTLY', 18)}}的其他基金
ALPHA-1 ANTITRYPSIN AND MACROPHAGE FUNCTION
ALPHA-1 抗胰蛋白酶和巨噬细胞功能
- 批准号:
7950744 - 财政年份:2008
- 资助金额:
$ 12.84万 - 项目类别:
CLINICAL TRIAL: PHASE 3 STUDY OF SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS
临床试验:吡非尼酮对患者安全性和有效性的第 3 阶段研究
- 批准号:
7950737 - 财政年份:2008
- 资助金额:
$ 12.84万 - 项目类别:
CLINICAL TRIAL: PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF RAAV1-CB-HAAT
临床试验:RAAV1-CB-HAAT 肌内注射 I 期试验
- 批准号:
7950715 - 财政年份:2008
- 资助金额:
$ 12.84万 - 项目类别:
PIRFENIDONE AND PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
吡非尼酮和特发性肺纤维化 (IPF) 患者
- 批准号:
7950773 - 财政年份:2008
- 资助金额:
$ 12.84万 - 项目类别:
CLINICAL TRIAL: TOBACCO SMOKE INDUCED CELL INJURY IN LUNG COMPARTMENTS
临床试验:烟草烟雾引起的肺室细胞损伤
- 批准号:
7950714 - 财政年份:2008
- 资助金额:
$ 12.84万 - 项目类别:
CLINICAL TRIAL: TOBACCO SMOKE INDUCED CELL INJURY IN LUNG COMPARTMENTS
临床试验:烟草烟雾引起的肺室细胞损伤
- 批准号:
7717092 - 财政年份:2007
- 资助金额:
$ 12.84万 - 项目类别:
CLINICAL TRIAL: PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF RAAV1-CB-HAAT
临床试验:RAAV1-CB-HAAT 肌内注射 I 期试验
- 批准号:
7717093 - 财政年份:2007
- 资助金额:
$ 12.84万 - 项目类别:
相似海外基金
Affinity Reagents and Sensor Platform Development for Blood Biochemical Monitoring
用于血液生化监测的亲和试剂和传感器平台开发
- 批准号:
10452054 - 财政年份:2022
- 资助金额:
$ 12.84万 - 项目类别:
Affinity Reagents and Sensor Platform Development for Blood Biochemical Monitoring
用于血液生化监测的亲和试剂和传感器平台开发
- 批准号:
10583518 - 财政年份:2022
- 资助金额:
$ 12.84万 - 项目类别:
Identification of Metabolic Phenotypes and Systemic Biochemical Reaction Networks Associated with Human Blood Pressure
与人体血压相关的代谢表型和全身生化反应网络的鉴定
- 批准号:
MR/S004033/1 - 财政年份:2018
- 资助金额:
$ 12.84万 - 项目类别:
Fellowship
Red Blood Cell Membrane: Organisation, Mechanics and Biochemical Signalling
红细胞膜:组织、力学和生化信号传导
- 批准号:
1783699 - 财政年份:2016
- 资助金额:
$ 12.84万 - 项目类别:
Studentship
Quantitative detection of endometrial cancer biomarkers in blood by biochemical techniques and mass spectrometry
生化技术和质谱法定量检测血液中子宫内膜癌生物标志物
- 批准号:
379133-2009 - 财政年份:2011
- 资助金额:
$ 12.84万 - 项目类别:
Postgraduate Scholarships - Doctoral
Quantitative detection of endometrial cancer biomarkers in blood by biochemical techniques and mass spectrometry
生化技术和质谱法定量检测血液中子宫内膜癌生物标志物
- 批准号:
379133-2009 - 财政年份:2010
- 资助金额:
$ 12.84万 - 项目类别:
Postgraduate Scholarships - Doctoral
Quantitative detection of endometrial cancer biomarkers in blood by biochemical techniques and mass spectrometry
生化技术和质谱法定量检测血液中子宫内膜癌生物标志物
- 批准号:
379133-2009 - 财政年份:2009
- 资助金额:
$ 12.84万 - 项目类别:
Postgraduate Scholarships - Doctoral
Computational & Biochemical Studies of the Malarial Blood Stage Invasion Complex
计算型
- 批准号:
7545695 - 财政年份:2008
- 资助金额:
$ 12.84万 - 项目类别:
A Multi-Scale Approach to Understanding the Mechanical and Biochemical Behavior of Tissue Engineered Blood Vessels
了解组织工程血管的机械和生化行为的多尺度方法
- 批准号:
0700507 - 财政年份:2007
- 资助金额:
$ 12.84万 - 项目类别:
Standard Grant